Health equity in the telehealth age has assumed added importance since the COVID-19 pandemic began. The Federal Communications Commission estimates that about 21 million Americans don't have access to the Internet in their homes. Other sources estimate it is closer to 162 million. However,Read Article
"If you're having trouble paying for your medications, Drug Company X may be able to help."
You may have heard sentences like this at the end of pharmaceutical ads on television, and some clinicians may wonder what exactly the companies do to help their patients. The help usuallyRead Article
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. How to handle COVID19 Vaccine issues, IL-6 inhibition in COVID, Comorbidites in RA, IVIG in dermatomyositis, & more...Read Article
2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related. Below, are our top news itemsRead Article
The ProDERM study design and outcomes are previewed in Medicine; and as promised the results were revealed at ACR Convergence in November 2020 showing that IVIg is safe, effective and superior to placebo i(PBO) in patients with dermatomyositis (DM).Read Article
The fate of the Trump administration's "most favored nation" (MFN) rule for bringing down prescription drug prices remains uncertain as President-elect Joe Biden prepares to assume office later this month.Read Article
Dr. Jack Cush reviews the news, journal articles and favorite blogs from this past week on RheumNow.com.Read Article